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Abstract. The processes of inflammation and fibrosis in patients with chronic obstructive pulmonary disease. 
Pertseva T.A., Konopkina L.I., Koval D.S., Guba Yu.V. The aim of the study was to determine the categories of 
COPD patients with a predominance of fibrotic or inflammatory processes. The study included 37 stable COPD 
patients (men – 33 (89.2%), women – 4 (10.8%), mean age – 63.5±1.18 years, the level of forced expiratory volume for 
the first second after the test with bronchodilators (FEV1post) – 46.7±5.81% of the proper value). To determine the 
categories of COPD patients with a predominance of inflammation or fibrosis, a cluster analysis was performed. For 
this purpose the most important indicators from a clinical point of view were selected: the number of exacerbations 
over the past year, dyspnea severity according to the mMRC scale, the level of FEV1 post and reversibility level in 
absolute values, systemic inflammation markers levels (CAA, C-RP) and profibrotic cytokine TGF-β1. Thus, according 
to the results of cluster analysis, two categories of patients were identified. The first category – COPD patients with a 
predominance of the inflammatory process with low dyspnea severity, high functional indicators (FEV1 >50% of the 
proper value), high airway reversibility level, low level of profibrotic cytokine TGF-β1, high levels of systematic 
inflammation markers (C-RP and CAA). The second category – COPD patients with a predominance of the fibrosis 
process, with a high dyspnea severity, low functional indicators (FEV1 ≤50% of the proper value), low airway 
reversibility level, low levels of systematic inflammation markers (C-RP and CAA), and high profibrotic cytokine TGF-
β1 levels. The prevalence of inflammatory processes was observed mainly in COPD patients, who belong to clinical 
group C; the prevalence of fibrotic processes – mainly in patients of clinical group B. 
 
Реферат. Процессы воспаления и фиброзирования у больных хроническим обструктивным заболеванием 
легких. Перцева Т.А., Конопкіна Л.И., Коваль Д.С., Губа Ю.В. Целью исследования было определить 
категории больных ХОЗЛ с превалированием процессов фиброзирования или воспаления. В исследование было 
включено 37 больных ХОЗЛ в стабильную фазу патологического процесса (мужчин – 33 (89,2%), женщин – 
4 (10,8%), средний возраст – 63,5 ± 1,18 года, уровень объема форсированного выдоха за первую секунду после 
пробы с бронхолитиками (ОФВ1пост) – 46,7 ± 5,81% должной величины). С целью определения категорий 
больных ХОЗЛ с превалированием процессов воспаления или фиброзирования был проведен кластерный анализ. 
Для этого были выбраны наиболее важные с клинической точки зрения показатели: количество обострений за 
прошлый год, выраженность одышки по шкале mMRC, уровень ОФВ1пост и прирост ОФВ1 в абсолютных 
величинах, уровни маркеров системного воспаления (САА, С-РП) и профибротического цитокина ТФР-β1. 
Согласно результатам кластерного анализа были выделены две категории больных. Первая категория – 
больные ХОЗЛ с преобладанием процесса воспаления с низкой выраженностью одышки, высокими функ-
циональными показателями (ОФВ1 > 50% должной величины), высоким уровнем обратимости бронхо-
обструкции, низким уровнем профибротического цитокина ТФР-β1, высокими уровнями маркеров системного 
воспаления (С-РП и САА). Вторая категория – больные ХОЗЛ с преобладанием процессов фиброзирования с 
высокой выраженностью одышки, низкими функциональными показателями (ОФВ1 ≤ 50% должной 
величины), низким уровнем обратимости бронхообструкции, низкими уровнями маркеров системного 
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воспаления (С-РП и САА), высоким уровнем профибротического цитокина ТФР-β1. Превалирование процессов 
воспаления наблюдалось преимущественно у больных ХОЗЛ, которые относятся к клинической группе С; 
превалирование процессов фиброзирования – преимущественно у больных ХОЗЛ клинической группы В.  
 
Fibrosis and inflammation are key links in the 
pathogenesis of chronic obstructive pulmonary 
disease (COPD). First of all, COPD is characterized 
by a chronic inflammatory process which in the 
early stages of the disease may be reversible. 
Without excluding etiological factors and in the 
absence of proper treatment, the inflammation per-
sists and becomes permanent. The main localization 
of inflammation is the small airways but it can be 
quite pronounced in the large bronchi, and in the 
pulmonary parenchyma, and in the pulmonary 
vessels [4, 13]. As the disease progresses, the 
inflammatory process becomes systemic with an 
increase in the levels of some markers of inflam-
mation in the peripheral blood [3, 11]. 
Fibrosis, which is a consequence of chronic 
inflammation, leads to morphological changes in all 
structures of the bronchi which, in turn, cause 
functional changes. According to modern ideas, 
airway remodeling begins quite early – during the 
first year of persistent inflammatory process [9, 10]. 
In recent years, more and more attention is paid 
to personalized therapy of patients with COPD, 
which is usually chosen taking into account the 
clinical manifestations of the disease and the levels 
of functional indicators. However, since fibrosis and 
inflammation are the main pathogenetic processes 
that lead to irreversible changes in lung tissues, the 
choice of basic therapy should take into account the 
prevalence of a pathological process. Determination 
of this prevalence at different stages of the disease 
can be done by assessing the levels of serum bio-
markers of fibrosis and inflammation [1, 7, 8, 15]. 
C-reactive protein (C-RP) remains one of the 
markers of inflammation available for determination 
in clinical practice. Although it is a non-specific, it is 
a sensitive clinical and laboratory indicator of 
inflammation which is synthesized in hepatocytes 
[11]. Another sensitive marker of inflammation in 
COPD is serum amyloid A (SAA), which, in con-
trast to C-RP, is produced not only in the liver but 
also directly in the inflammatory focus [6]. 
Of interest is also the possibility of non-invasive 
diagnosis of fibrosis of the lung tissue and bronchial 
wall using serum biomarkers. Thus, the transforming 
growth factor-β1 (TGF-β1) is one of the main 
factors leading to structural changes in the bronchial 
wall and the appearance of an irreversible com-
ponent of airway obstruction [9, 13]. 
There is a small amount of data in the literature 
comparing the nature and severity of clinical 
manifestations of COPD, on the one hand, and the 
levels of serum biomarkers of fibrosis and inflam-
mation, on the other [10]. 
Thus, the aim of our study was to establish the 
categories of patients with COPD according to the 
prevalence of markers of systemic inflammation or 
markers of fibrosis. 
MATERIALS AND METHODS OF RESEARCH  
We examined 37 patients with COPD with II-IV 
degree of ventilation disorders according to the 
GOLD classification [9] (clinical group B – 
21 people (56.8%), clinical group C – 11 people 
(29.7%), clinical group D – 5 people (13.5%)) in the 
stable phase of the pathological process (men – 33 
(89.2%), women – 4 (10.8%), mean age – 63.5±1.18 
years, the level of forced expiratory volume in the 
first second after the test with a bronchodilator 
(FEV1post) – 46.7±5.81% of the appropriate value. 
The formulation of the clinical diagnosis of 
COPD was performed in accordance with inter-
national and national recommendations [1]. 
All subjects agreed to participate in the study. 
Prior to inclusion in the study, all patients were in 
the stable phase of the disease for at least two 
months. None of the patients had severe exa-
cerbations of COPD during the last year. 
Criteria for exclusion of patients from the study 
were: 
1) refusal to participate in the study; 
2) the presence of bronchial asthma or other 
diseases with bronchoobstructive syndrome; 
3) the presence of severe clinically significant 
cardiovascular pathology in the anamnesis and/or at 
the time of examination, which may lead to an 
increase in both markers of systemic inflammation 
and markers of fibrosis, in particular acute myo-
cardial infarction, acute cerebrovascular accident; 
4) liver disease (hepatitis, cirrhosis, severe liver 
failure) in the anamnesis and/ or at the time of exa-
mination, as they are characterized by an increase in 
the level of the marker TGF-β 1 in the serum; 
5) increase in liver enzymes by more than 2.5 
times, as high levels of liver enzymes indicate the 
presence of liver disease, which can lead to 
increased levels of TGF-β 1; 
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6) history of kidney disease and/or at the time of 
examination, in particular CKD, which may lead to 
increased levels of CAA and C-RP; 
7) the presence of oncological diseases in the 
anamnesis and / or at the time of examination, which 
may lead to an increase in the level of CAA; 
8) injuries and operations suffered during the last 
two years; 
9) abuse of alcohol and/or drugs. 
Thus, the patients included in the study did not 
have concomitant pathology that could affect 
markers of systemic inflammation or fibrosis. 
Examination of patients included evaluation of 
complaints, including the severity of dyspnea by 
the mMRC scale (The Modified Medical Research 
Council Dyspnea Scale (mMRC)), medical history 
and physical examination. To determine the 
ventilatory function of the lungs, spirometry was 
performed on a “Master Screen Body/Diff” device 
(“Jaeger”, Germany) with an estimate of the 
forced exhalation volume in the first second 
(FEV1), forced vital capacity of the lungs (FVC), 
the ratio of FEV1/ FVC before and after the test 
with a bronchodilator (salbutamol 400 mg), an 
increase in FEV1 [5, 14]. 
To determine the severity of systemic inflam-
mation in all subjects, the plasma level of C-RP 
(mg/l) was measured by immunoturbodimetric 
method and serum CAA level (pg/ml) by enzyme-
linked immunosorbent assay. To determine the 
severity of the fibrosis process in all patients, the 
serum level of fibrosis marker TGF-β1 (ng/ml) was 
measured, which was determined by enzyme-linked 
immunosorbent assay. Collection of biological 
material was performed in the morning on an empty 
stomach [4, 6, 13]. 
The obtained results were processed using 
biometric analysis methods using the program 
"STATISTICA 6.1" ("StatSoftInc.", Serial 
N AGAR909E415822FA). The differences were 
assessed according to the criteria of Student, Mann-
Whitney and Pearson. Statistical methods included 
parametric and nonparametric. The analysis of 
indicators with normal distribution was performed 
according to the mean value and the error of the 
mean, with abnormal distribution - according to the 
median and quartiles (Me [25-75]). Cluster analysis 
was used to determine the categories of patients with 
COPD with a predominance of fibrosis or inflam-
mation [2]. Differences between groups at p<0.05 
were considered significant. 
RESULTS AND DISCUSSION 
In order to determine the categories of patients 
with COPD with a predominance of inflammation or 
fibrosis, a cluster analysis was performed. For this 
purpose, the most clinically important indicators 
were selected: the number of exacerbations over the 
past year, the severity of dyspnea by the mMRC 
scale, FEV1post levels and FEV1 increase in absolute 
values, levels of systemic inflammatory markers 
CAA, C-RP and profibrotic cytokine TGF-β1. 
Because the studied traits are measured in 
different units, the absolute values were stan-
dardized. Each variable had a mean (0) and standard 
(1) deviation. Hierarchical classification was chosen 
for the formation of clusters, as a rule of pooling – 
the method of single communication, as a measure 
of proximity – Euclidean distance. Tree-like clus-
tering was carried out according to Ward's clustering 
strategy. The hierarchical cluster tree demonstrates 
the mechanism of sequential pooling of patients of 
two classes into one consecutive, indicating the 
distances between them. To determine the threshold 
distance, a diagram of the pooling process was used, 
which showed that the refractive point falls on the 
35th clustering step, and the distance of pooling is 
12. The number of clusters into which all patients 
were divided was determined by the formula: (n-m), 
where n is the total number of observations, and m is 
the step of the refractive point. Thus, the number of 
clusters was 2 (37-35=2). 
The correctly chosen number of clusters was 
confirmed by constructing a dendrogram (Fig. 1). 
At the threshold distance 12 there are two 
intersections of the perpendicular with the 
"branches" of the dendrogram. The number of 
intersections determines the number of clusters, 
and the objects below the truncated branch are the 
composition of the clusters.  
After forming a hypothesis to determine the 
number of clusters, the k-means method was used. 
The clustering algorithm showed that patients who 
belonged to different clusters had a significant 
difference between the levels of indicators (p<0.05), 
which indicates the correctness of the found cluster 
solution. According to cluster analysis, a significant 
difference was found. To visualize the differences 
between the indicators, their linear graphs were 
constructed (Fig. 2). 
In order to determine those clinical features of 
COPD that are most consistent with the prevalence 
of systemic inflammation or fibrosis, it was 
appropriate to determine the level of clinical, 
functional and laboratory parameters in each cluster. 
No age and gender differences were found in the 
clusters. At the same time, they differed significantly 
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Fig. 1. Hierarchical tree 
 
Cluster 1 included patients with relatively mild 
bronchoobstruction (FEV1post. ≥50% of the appro-
priate value), a high level of its reversibility 
(≥200 ml), low severity of shortness of breath (0 – 
1 point by the mMRC scale), low levels of 
profibrotic cytokine TGF-β ≤6.0 ng/ml). At the 
same time, these patients had a high frequency of 
mild exacerbations (≥2 per year) and a significant 
severity of systemic inflammation both in terms of 
C-RP (>5.0 mg/l) and CAA levels (>500 ng/ml).  
Cluster 2 included patients with more severe 
bronchoobstruction (FEV1post. ≤50.0% of the 
appropriate value), low reversibility (<200 ml), 
significant severity of shortness of breath (≥2 
points by the mMRC scale), with a low frequency 
of mild exacerbations (≤1 per year) and low 
severity of systemic inflammation both at the level 
of C-RP (<5.9 mg/l) and at the level of CAA 
(<400.0 ng/ml). At the same time, these were 
patients with high levels of the profibrotic 
cytokine TGF-β1 (>6.0 ng/ml). 
Thus, according to the results of cluster 
analysis, two categories of patients were iden-
tified: the first – with a predominance of inflam-
matory processes; the second - with a predomi-
nance of fibrosis processes. 
When comparing the individual data obtained 
in the clusters and comparing them with the 
current classification of COPD by clinical groups 
[1], it was found that cluster 1 included mainly 
patients of clinical group C (10 (83.3%) people), 
cluster 2 – mainly patients of clinical group B (20 
(80.0%) people). Patients of clinical group D were 
almost evenly distributed between the two clusters 
(2 patients entered cluster 1, 3 – cluster 2), al-
though their total number was low and did not 
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Fig. 2. Clusters of patients with COPD according to clinical and anamnestic data,  
indicators of lung ventilation function, markers of inflammation and fibrosis 
 
Determining the categories of patients with 
COPD with a predominance of inflammation or 
fibrosis by determining the levels of markers of 
systemic inflammation (C-RP, CAA) and fibrosis 
(TGF-β1) allows to obtain the most reliable data for 
individualization of management tactics. Thus, 
according to some studies [3, 12], the use of inhaled 
glucocorticosteroids in the basic therapy of COPD 
helps to reduce the severity of systemic inflam-
mation, and cholinolytics and long-acting β2-
agonists control the level of TGF-β1 [9]. However, 
further research is needed to determine the impact of 
basic therapy of COPD patients on the severity of 
inflammation and fibrosis. 
 
Levels of indicators of COPD patients included in the clusters 
Clusters 
Indicators 
1, n=12 2, n=25 
p 










Age (years), M±m 65.1±1.72 61.1±5.6 0.771 
Number of exacerbations over the past year 2.0±0.22 1.1±0.15 0.001 
Shortness of breath by mMRC, points 1 [1‒1] 2 [1‒3] 0.028 
Level of FEV1post. (% of appropriate value) 58.3±4.2 45.5±2.8 0.029 
Increase in FEV1, ml 250±0.04 100±0.02 0.001 
Level of C-RP, mg/l 9.25 [5.6‒17.3] 4.8 [2.9‒5.9] 0.037 
Level of CAA ng/ml 695.3 [502.6‒2980.1] 247.5 [217.8‒406.3] 0.026 
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Fig. 3. Division of patients included in the clusters into clinical groups of COPD 
 
CONCLUSIONS 
1. Patients with COPD with a predominance of 
inflammation have a slight severity of shortness of 
breath, moderate bronchoobstruction (FEV1>50% of 
the appropriate value), high reversibility of bronchial 
obstruction, low profibrotic cytokine TGF-β1, high 
levels of markers of systemic inflammation (C-RP 
and CAA). 
2. Patients with COPD with a predominance of 
the fibrosis process have a significant severity of 
shortness of breath, a significant level of bronchial 
obstruction (FEV1≤50% of the appropriate value), a 
low level of reversibility.  
3. Bronchial obstruction, low levels of markers of 
systemic inflammation (C-RP and CAA), high levels 
of profibrotic cytokine TGF-β1.  
4. The prevalence of inflammatory processes is 
observed mainly in patients with COPD who belong 
to clinical group C; prevalence of fibrosis processes 
– mainly in patients with COPD of clinical group B.  
Conflict of interests. The authors declare no 
conflict of interest. 
REFERENCES 
1. Feschenko YuI, Gavrisyuk VK, Dzyublik OYa, 
Mostovoy YuM, Pertseva TO, Polyanska MO, Yachnik AI, 
Yashina LO. [Adapted clinical guidelines: Chronic 
obstructive pulmonary disease (part 1)]. Ukrayinskiy 
pulmonologichniy zhurnal. 2019;2:5-18. Ukrainian.  
doi: https://doi.org/10.31215/2306-4927-2019-104-2-5-18  
2. Antomonov MYu. Mathematical processing and 
analysis of medical and biological data. 2nd ed]. Kyiv: 
Medinform; 2018. p. 579. Russian. Available from: 
https://www.olx.ua/.../antomonov-m-yu-monografya  
3. Konopkina LI. [Approaches to the treatment of 
patients with chronic obstructive pulmonary disease, 
depending on phenotypes]. Ukrainskyi pulmonologichnyi 
zhurnal. 2016;2:56-57. Ukrainian. Available from: 
http://nbuv.gov.ua/UJRN/Upj_2016_2_31 
4. Agusti A, Gea J, Faner R. Biomarkers, the control 
panel and personalized. COPD medicine. 2016;21(1):24-
33. doi: https://doi.org/10.1111/resp.12585 
5. Clinical COPD Questionnaire Calculating. 
[Internet]. Available from: http://ccq.nl/?page_id=342 
6. Tian-Lai Lin, Wei-Wen Chen, Zhi-Rong Ding, 
Si-Can Wei, Ming-Lian Huang, Cai-Hui Li Correlations 
between serum amyloid A, C-reactive protein and clinical 
indices of patients with acutely exacerbated chronic 
obstructive. J Clin Lab Anal. 2019;33(4):e22831. 
doi: https://doi.org/10.1002/jcla.22831 
7. Jean Bourbeaua, Mohit Bhutanib, Paul Her-
nandezc, Darcy D Marciniukd, Shawn D. Aaron CTS 
position statement: Pharmacotherapy in patients with 
COPD. 2017;1(4):222-41. 
doi: https://doi.org/10.1080/24745332.2017.1395588 
8. Global initiative for chronic obstructive lung 
disease (GOLD). Global strategy for diagnosis, mana-
gement, and prevention of chronic obstructive pulmonary 
disease. Update 2020. [Internet]. Available from: 
https://goldcopd.org/wp-content/uploads/2019/12/GOLD-
2020-FINAL-ver1.2-03Dec19_WMV.pdf 
9. Kai M Beeh, Pierre-Regis Burgel, Frits ME Fran-
ssen, Jose Luis Lopez-Campos, Stelios Loukides et al. 
How Do Dual Long-Acting Bronchodilators Prevent Exa-
cerbations of Chronic Obstructive Pulmonary Disease? 
Am J Respir Crit Care Med. 2017;196(2):139-49. 
doi: https://doi.org/10.1164/rccm.201609-1794CI 
10. Stephen I Rennard, Nicholas Locantore, Bruno De-
lafont, Ruth Tal-Singer, Edwin K Silverman, Jorgen Vestbo, 
Bruce E Miller, Per Bakke, Bartolomé Celli. Identification of 
Five Chronic Obstructive Pulmonary Disease Subgroups 
with Different Prognoses in the ECLIPSE Cohort Using Clu-
Cluster 1 Cluster 2 
 Clinical group D 
 Clinical group C 
 Clinical group B 
 
МЕДИЧНІ ПЕРСПЕКТИВИ / MEDICNI PERSPEKTIVI 
 6520/ Vol. XXV / 4 
ster Analysis. Ann Am Thorac Soc. 2015 Mar;12(3):303-12. 
doi: https://doi.org/10.1513/AnnalsATS.201403-125OC 
11. Zijing Chen, Vincent S Fan, Kenneth Pike, Na-
than Yee, Soo Borson, Sandra Adams, Ruth Kohen, et al. 
Increased Physical Activity Associated with De-
creased   IL-6 and CRP in Patients with COPD. Am J 
Respir Crit Care Med. 2017;195:1026-33. Available 
from: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm
-conference.2017.195.1_MeetingAbstracts.A1033. 
12. Wouters EF, Wouters BB, Augustin IM, Frans-
sen FM. Personalized medicine and chronic obstructive pul-
monary disease. Curr Opin Pulm Med. 2017 May;23(3):241-
6. doi: https://doi.org/10.1097/MCP.0000000000000377 
13. Akira Saito, Masafumi Horie, Takahide. Nagase 
TGF-β Signaling in Lung Health and Disease. Int J Mol 
Sci. 2018 Aug 20;19(8):2460. 
doi: https://doi.org/10.3390/ijms19082460 
14. Brian L Graham, Irene Steenbruggen, Martin R 
Miller, Igor Z Barjaktarevic, Brendan G. Cooper, Gra-
ham L. Hal. Standardization of Spirometry 2019. Update. 
An Official American Thoracic Society and European 
Respiratory Society Technical Statement. Am J Respir 
Crit Care Med. 2019;200(8):70-e88. 
doi: https://doi.org/10.1164/rccm.201908-1590ST  
15. Ana M Menezes, Fernando C Wehrmeister, Ro-
gelio Perez-Padilla, Karynna P Viana, Claudia Soares, 
Hana Mullerova, et al. The PLATINO study: 
description of the distribution, stability, and mortality 
according to the Global Initiative for Chronic 
Obstructive Lung Disease classification from 2007 to 
2017. Int J Chron Obstruct Pulmon Dis. 2017;12:1491-
501. doi: https://doi.org/10.2147/COPD.S136023 
СПИСОК ЛІТЕРАТУРИ 
1. Адаптована клінічна настанова: Хронічне 
обструктивне захворювання легень. Ч. 1. / Ю. І. Фе-
щенко та ін. Укр. пульмонологічний журнал. 2019, 
№2. С.5-18.  
DOI: https://doi.org/10.31215/2306-4927-2019-104-2-5-18 
2. Антомонов М. Ю. Математическая обработка 
и анализ медико-биологических данных. 2-е изд. Київ: 
МИЦ «Мединформ», 2018. 579 с. 
URL: https://www.olx.ua/.../antomonov-m-yumonografya 
3. Конопкина Л. И. Подходы к лечению больных 
хроническим обструктивным заболеванием легких в 
зависимости от фенотипов. Укр. пульмонологічний 
журнал. 2016. № 2. С. 56-57. 
URL: http://nbuv.gov.ua/UJRN/Upj_2016_2_31 
4. Biomarkers, the control panel and personalized 
COPD medicine / A. Agusti et al. Respirology. 2016. 
Vol. 21. P. 24-33. DOI: https://doi.org/10.1111/resp.12585 
5. Clinical COPD Questionnaire Calculating. 
URL: http://ccq.nl/?page_id=342 
6. Correlations between serum amyloid A, Creactive 
protein and clinical indices of patients with acutely 
exacerbated chronic obstructive / Tian‐Lai Lin et al. 
J Clin Lab Anal. 2019. Vol. 33, No. 4. P. e22831. 
DOI: https://doi.org/10.1002/jcla.22831 
7. CTS position statement: Pharmacotherapy in 
patients with COPD / J. Bourbeau et al. Canadian journal 
of respiratory, critical care, and sleep medicine. 2017. 
Vol. 4, No. 4. P. 222-241. 
DOI: https://doi.org/10.1080/24745332.2017.1395588 
8. Global initiative for chronic obstructive lung 
disease (GOLD). Global strategy for diagnosis, mana-
gement, and prevention of chronic obstructive pulmonary 
disease. Update 2019. P. 14 
URL: http://www.goldcopd.org/uploads/users/files/GOL
D_Report_2014_Jan23.pdf 
9. How Do Dual Long-Acting Bronchodilators Pre-
vent Exacerbations of Chronic Obstructive Pulmonary 
Disease? / Kai M. Beeh et al. Am J Respir Crit Care Med. 
2017. Vol. 196, No. 2. P. 139-149. 
DOI: https://doi.org/10.1164/rccm.201609-1794CI 
10. Identification of Five Chronic Obstructive Pul-
monary Disease Subgroups with Different Prognoses in 
the ECLIPSE Cohort Using Cluster Analysis / 
S. I. Rennard et al. Annals ATS. 2015. Vol. 12. P. 303-312. 
DOI: https://doi.org/10.1513/AnnalsATS.201403-125OC 
11. Increased Physical Activity Associated with 
Decreased IL-6 and CRP in Patients with COPD / 
Z. Chen et al. American Journal of Respiratory and 
Critical Care Medicine. 2017. Vol. 195. P. 1026-1033. 
URL: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm
-conference.2017.195.1_MeetingAbstracts.A1033 
12. Wouters E. F., Wouters B. B., Augustin I. M., 
Franssen F. M. Personalized medicine and chronic ob-
structive pulmonary disease. Curr Opin Pulm Med. 
2017. Vol. 23, No. 3. P. 241-246. 
DOI: https://doi.org/10.1097/MCP.0000000000000377 
13. Saito A. TGF-β Signaling in Lung Health and 
Disease / Saito A. et al. J Mol Sci. 2018. Vol. 19, No. 8. 
P. 2460. DOI: https://doi.org/10.3390/ijms19082460 
14. Spirometry 2019 Update An Official American 
Thoracic Society and European Respiratory Society 
Technical Statement / Brian L. et al. Am J Respir Crit 
Care Med. 2019. Vol. 200. No. 8. P. 70-88. 
DOI: https://doi.org/10.1164/rccm.201908-1590ST  
15. The PLATINO study: description of the distr-
ibution, stability, and mortality according to the Global 
Initiative for Chronic Obstructive Lung Disease clas-
sification from 2007 to 2017 / Menezes AM et al. Int J 
Chron Obstruct Pulmon Dis. 2017. Vol. 12. P. 1491-
1501. DOI: https://doi.org/10.2147/COPD.S136023 
The article was received 
2020.09.19 
 
 
